Search

Your search keyword '"McAlpine, Jessica N."' showing total 253 results
Start Over Author "McAlpine, Jessica N." Search Limiters Full Text
253 results on '"McAlpine, Jessica N."'

1. AI-based histopathology image analysis reveals a distinct subset of endometrial cancers

Author

Darbandsari, Amirali, Farahani, Hossein, Asadi, Maryam, Wiens, Matthew, Cochrane, Dawn, Khajegili Mirabadi, Ali, Jamieson, Amy, Farnell, David, Ahmadvand, Pouya, Douglas, Maxwell, Leung, Samuel, Abolmaesumi, Purang, Jones, Steven J. M., Talhouk, Aline, Kommoss, Stefan, Gilks, C. Blake, Huntsman, David G., Singh, Naveena, McAlpine, Jessica N., and Bashashati, Ali

Published
2024
Full Text
View/download PDF

3. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

Author

Glubb, Dylan M, Thompson, Deborah J, Aben, Katja KH, Alsulimani, Ahmad, Amant, Frederic, Annibali, Daniela, Attia, John, Barricarte, Aurelio, Beckmann, Matthias W, Berchuck, Andrew, Bermisheva, Marina, Bernardini, Marcus Q, Bischof, Katharina, Bjorge, Line, Bodelon, Clara, Brand, Alison H, Brenton, James D, Brinton, Louise A, Bruinsma, Fiona, Buchanan, Daniel D, Burghaus, Stefanie, Butzow, Ralf, Cai, Hui, Carney, Michael E, Chanock, Stephen J, Chen, Chu, Chen, Xiao Qing, Chen, Zhihua, Cook, Linda S, Cunningham, Julie M, De Vivo, Immaculata, deFazio, Anna, Doherty, Jennifer A, Dörk, Thilo, du Bois, Andreas, Dunning, Alison M, Dürst, Matthias, Edwards, Todd, Edwards, Robert P, Ekici, Arif B, Ewing, Ailith, Fasching, Peter A, Ferguson, Sarah, Flanagan, James M, Fostira, Florentia, Fountzilas, George, Friedenreich, Christine M, Gao, Bo, Gaudet, Mia M, Gawełko, Jan, Gentry-Maharaj, Aleksandra, Giles, Graham G, Glasspool, Rosalind, Goodman, Marc T, Gronwald, Jacek, Harris, Holly R, Harter, Philipp, Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle AT, Hillemanns, Peter, Høgdall, Estrid, Høgdall, Claus K, Holliday, Elizabeth G, Huntsman, David G, Huzarski, Tomasz, Jakubowska, Anna, Jensen, Allan, Jones, Michael E, Karlan, Beth Y, Karnezis, Anthony, Kelley, Joseph L, Khusnutdinova, Elza, Killeen, Jeffrey L, Kjaer, Susanne K, Klapdor, Rüdiger, Köbel, Martin, Konopka, Bozena, Konstantopoulou, Irene, Kopperud, Reidun K, Koti, Madhuri, Kraft, Peter, Kupryjanczyk, Jolanta, Lambrechts, Diether, Larson, Melissa C, Le Marchand, Loic, Lele, Shashikant, Lester, Jenny, Li, Andrew J, Liang, Dong, Liebrich, Clemens, Lipworth, Loren, Lissowska, Jolanta, Lu, Lingeng, Lu, Karen H, Macciotta, Alessandra, Mattiello, Amalia, May, Taymaa, McAlpine, Jessica N, and McGuire, Valerie

Subjects
Epidemiology, Biomedical and Clinical Sciences, Health Sciences, Oncology and Carcinogenesis, Human Genome, Uterine Cancer, Genetics, Biotechnology, Ovarian Cancer, Prevention, Cancer, Rare Diseases, 2.1 Biological and endogenous factors, Aetiology, Carcinoma, Ovarian Epithelial, Endometrial Neoplasms, Female, Genome-Wide Association Study, Humans, Ovarian Neoplasms, Quantitative Trait Loci, Risk Factors, OPAL Study Group, AOCS Group, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundAccumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers.MethodsUsing LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data.ResultsGenetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10-5). We found seven loci associated with risk for both cancers (P Bonferroni < 2.4 × 10-9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation.ConclusionsUsing cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis.ImpactOur research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.

Published
2021

4. Single-cell genomic variation induced by mutational processes in cancer

Author

Funnell, Tyler, O’Flanagan, Ciara H., Williams, Marc J., McPherson, Andrew, McKinney, Steven, Kabeer, Farhia, Lee, Hakwoo, Salehi, Sohrab, Vázquez-García, Ignacio, Shi, Hongyu, Leventhal, Emily, Masud, Tehmina, Eirew, Peter, Yap, Damian, Zhang, Allen W., Lim, Jamie L. P., Wang, Beixi, Brimhall, Jazmine, Biele, Justina, Ting, Jerome, Au, Vinci, Van Vliet, Michael, Liu, Yi Fei, Beatty, Sean, Lai, Daniel, Pham, Jenifer, Grewal, Diljot, Abrams, Douglas, Havasov, Eliyahu, Leung, Samantha, Bojilova, Viktoria, Moore, Richard A., Rusk, Nicole, Uhlitz, Florian, Ceglia, Nicholas, Weiner, Adam C., Zaikova, Elena, Douglas, J. Maxwell, Zamarin, Dmitriy, Weigelt, Britta, Kim, Sarah H., Da Cruz Paula, Arnaud, Reis-Filho, Jorge S., Martin, Spencer D., Li, Yangguang, Xu, Hong, de Algara, Teresa Ruiz, Lee, So Ra, Llanos, Viviana Cerda, Huntsman, David G., McAlpine, Jessica N., Shah, Sohrab P., and Aparicio, Samuel

Published
2022
Full Text
View/download PDF

5. Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification

Author

Thompson, Emily F., Huvila, Jutta, Jamieson, Amy, Leung, Samuel, Lum, Amy, Offman, Saul, Lytwyn, Alice, Sur, Mona Lisa, Hoang, Lynn, Irving, Julie, van der Westhuizen, Nicholas, Morin, Chantale, Bicamumpaka, Cyrille, Azordegan, Nazilla, Gougeon, François, Ennour-Idrissi, Kaoutar, Senz, Janine, McConechy, Melissa K., Aguirre-Hernandez, Rosalia, Lui, Victoria, Kuo, Carolyn, Bell, Cassidy, Salisbury, Taylor, Lawson, James, He, Ellen, Wang, Shanzhao, Chiu, Derek, Kean, Sarah, Samouëlian, Vanessa, Salvador, Shannon, Gotlieb, Walter, Helpman, Limor, Scott, Stephanie, Wohlmuth, Christoph, Vicus, Danielle, Plante, Marie, Talhouk, Aline, Huntsman, David, Parra-Herran, Carlos, Kinloch, Mary, Grondin, Katherine, Gilks, C. Blake, and McAlpine, Jessica N.

Published
2022
Full Text
View/download PDF

6. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type

Author

Ji, Jennifer X, Cochrane, Dawn R, Tessier-Cloutier, Basile, Chen, Shary Yutin, Ho, Germain, Pathak, Khyatiben V, Alcazar, Isabel N, Farnell, David, Leung, Samuel, Cheng, Angela, Chow, Christine, Colborne, Shane, Negri, Gian Luca, Kommoss, Friedrich, Karnezis, Anthony, Morin, Gregg B, McAlpine, Jessica N, Gilks, C Blake, Weissman, Bernard E, Trent, Jeffrey M, Hoang, Lynn, Pirrotte, Patrick, Wang, Yemin, and Huntsman, David G

Subjects
Biotechnology, Ovarian Cancer, Cancer, Rare Diseases, Orphan Drug, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, Aetiology, Animals, Arginine, Argininosuccinate Synthase, Carcinoma, Small Cell, Cell Line, Tumor, Cell Proliferation, Female, Humans, Hydrolases, Mice, Ovarian Neoplasms, Ovary, Parathyroid Hormone-Related Protein, Polyethylene Glycols, Proteomics, Xenograft Model Antitumor Assays, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMany rare ovarian cancer subtypes, such as small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), have poor prognosis due to their aggressive nature and resistance to standard platinum- and taxane-based chemotherapy. The development of effective therapeutics has been hindered by the rarity of such tumors. We sought to identify targetable vulnerabilities in rare ovarian cancer subtypes.Experimental designWe compared the global proteomic landscape of six cases each of endometrioid ovarian cancer (ENOC), clear cell ovarian cancer (CCOC), and SCCOHT to the most common subtype, high-grade serous ovarian cancer (HGSC), to identify potential therapeutic targets. IHC of tissue microarrays was used as validation of arginosuccinate synthase (ASS1) deficiency. The efficacy of arginine-depriving therapeutic ADI-PEG20 was assessed in vitro using cell lines and patient-derived xenograft mouse models representing SCCOHT.ResultsGlobal proteomic analysis identified low ASS1 expression in ENOC, CCOC, and SCCOHT compared with HGSC. Low ASS1 levels were validated through IHC in large patient cohorts. The lowest levels of ASS1 were observed in SCCOHT, where ASS1 was absent in 12 of 31 cases, and expressed in less than 5% of the tumor cells in 9 of 31 cases. ASS1-deficient ovarian cancer cells were sensitive to ADI-PEG20 treatment regardless of subtype in vitro. Furthermore, in two cell line mouse xenograft models and one patient-derived mouse xenograft model of SCCOHT, once-a-week treatment with ADI-PEG20 (30 mg/kg and 15 mg/kg) inhibited tumor growth in vivo.ConclusionsPreclinical in vitro and in vivo studies identified ADI-PEG20 as a potential therapy for patients with rare ovarian cancers, including SCCOHT.

Published
2020

9. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

Author

Kommoss, Felix KF, Karnezis, Anthony N, Kommoss, Friedrich, Talhouk, Aline, Taran, Florin-Andrei, Staebler, Annette, Gilks, C Blake, Huntsman, David G, Krämer, Bernhard, Brucker, Sara Y, McAlpine, Jessica N, and Kommoss, Stefan

Subjects
Cancer, 2.1 Biological and endogenous factors, Aetiology, Aged, Aged, 80 and over, Cohort Studies, Endometrial Neoplasms, Female, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasm Staging, Neural Cell Adhesion Molecule L1, Prognosis, Survival Analysis, Tumor Suppressor Protein p53, Up-Regulation, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort.MethodsProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated.ResultsExpression of L1CAM was most frequent in p53 abnormal tumours (80%). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p

Published
2018

11. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification

Author

Karnezis, Anthony N, Leung, Samuel, Magrill, Jamie, McConechy, Melissa K, Yang, Winnie, Chow, Christine, Kobel, Martin, Lee, Cheng-Han, Huntsman, David G, Talhouk, Aline, Kommoss, Friederich, Gilks, C Blake, and McAlpine, Jessica N

Subjects
Genetics, Cancer, endometrial cancer, prognosis, biomarker, TCGA, ProMisE, L1CAM, progesterone receptor, estrogen receptor
Abstract

Molecular subclassification of endometrial carcinoma (EC) with Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) identifies four subtypes [DNA polymerase epsilon (POLE) mutant, mismatch repair-deficient, p53 wild-type (wt), and p53 abnormal]. The aim of this study was to evaluate additional EC biomarkers in the context of these subtypes. Tissue microarrays encompassing 460 previously characterized ECs were assessed for L1-cell adhesion molecule (L1CAM), progesterone receptor (PR), estrogen receptor (ER) alpha, stathmin, and phosphatase and tensin homolog (PTEN), by immunohistochemistry (IHC). Associations with clinicopathological parameters, molecular subtype, and outcomes were determined. About 413 ECs (75% endometrioid, >15% serous) had complete data. L1CAM overexpression was found in 16%, associated with older age, lower body mass index (BMI), advanced stage, grade 3 (97%), non-endometrioid histology (84%), deep myometrial invasion, lymphovascular space invasion (LVSI), and ER-negative, PR-negative status. Tumours overexpressing L1CAM were associated with poor outcomes {hazard ratio (HR) [95% confidence interval (CI)] 3.35 [2.10-5.23] for disease-specific survival [DSS], p

Published
2017

12. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Author

Kang, Eun Young, Cheasley, Dane, LePage, Cecile, Wakefield, Matthew J., da Cunha Torres, Michelle, Rowley, Simone, Salazar, Carolina, Xing, Zhongyue, Allan, Prue, Bowtell, David D.L., Mes-Masson, Anne-Marie, Provencher, Diane M., Rahimi, Kurosh, Kelemen, Linda E., Fasching, Peter A., Doherty, Jennifer A., Goodman, Marc T., Goode, Ellen L., Deen, Suha, Pharoah, Paul D.P., Brenton, James D., Sieh, Weiva, Mateoiu, Constantina, Sundfeldt, Karin, Cook, Linda S., Le, Nhu D., Anglesio, Michael S., Gilks, C. Blake, Huntsman, David G., Kennedy, Catherine J., Traficante, Nadia, Bowtell, D., Chenevix-Trench, G., Green, A., Webb, P., DeFazio, A., Gertig, D., Traficante, N., Fereday, S., Moore, S., Hung, J., Harrap, K., Sadkowsky, T., Pandeya, N., Malt, M., Mellon, A., Robertson, R., Bergh, T. Vanden, Jones, M., Mackenzie, P., Maidens, J., Nattress, K., Chiew, Y.E., Stenlake, A., Sullivan, H., Alexander, B., Ashover, P., Brown, S., Corrish, T., Green, L., Jackman, L., Ferguson, K., Martin, K., Martyn, A., Ranieri, B., White, J., Jayde, V., Mamers, P., Bowes, L., Galletta, L., Giles, D., Hendley, J., Alsop, K., Schmidt, T., Shirley, H., Ball, C., Young, C., Viduka, S., Tran, Hoa, Bilic, Sanela, Glavinas, Lydia, Brooks, Julia, Stuart-Harris, R., Kirsten, F., Rutovitz, J., Clingan, P., Glasgow, A., Proietto, A., Braye, S., Otton, G., Shannon, J., Bonaventura, T., Stewart, J., Begbie, S., Friedlander, M., Bell, D., Baron-Hay, S., Ferrier, A., Gard, G., Nevell, D., Pavlakis, N., Valmadre, S., Young, B., Camaris, C., Crouch, R., Edwards, L., Hacker, N., Marsden, D., Robertson, G., Beale, P., Beith, J., Carter, J., Dalrymple, C., Houghton, R., Russell, P., Links, M., Grygiel, J., Hill, J., Brand, A., Byth, K., Jaworski, R., Harnett, P., Sharma, R., Wain, G., Ward, B., Papadimos, D., Crandon, A., Cummings, M., Horwood, K., Obermair, A., Perrin, L., Wyld, D., Nicklin, J., Davy, M., Oehler, M.K., Hall, C., Dodd, T., Healy, T., Pittman, K., Henderson, D., Miller, J., Pierdes, J., Blomfield, P., Challis, D., McIntosh, R., Parker, A., Brown, B., Rome, R., Allen, D., Grant, P., Hyde, S., Laurie, R., Robbie, M., Healy, D., Jobling, T., Manolitsas, T., McNealage, J., Rogers, P., Susil, B., Sumithran, E., Simpson, I., Phillips, K., Rischin, D., Fox, S., Johnson, D., Lade, S., Loughrey, M., O'Callaghan, N., Murray, W., Waring, P., Billson, V., Pyman, J., Neesham, D., Quinn, M., Underhill, C., Bell, R., Ng, L.F., Blum, R., Ganju, V., Hammond, I., Leung, Y., McCartney, A., Buck, M., Haviv, I., Purdie, D., Whiteman, D., Zeps, N., DeFazio, Anna, Kaufmann, Scott, Churchman, Michael, Gourley, Charlie, Stephens, Andrew N., Meagher, Nicola S., Ramus, Susan J., Antill, Yoland C., Campbell, Ian, Scott, Clare L., Köbel, Martin, Gorringe, Kylie L., Ryland, Georgina L., Allan, Prue E., Alsop, Kathryn, Ananda, Sumitra, Au-Yeung, George, Böhm, Maret, Brand, Alison, Chenevix-Trench, Georgia, Christie, Michael, Chiew, Yoke-Eng, Dudley, Rhiannon, Fairweather, Nicole, Fereday, Sian, Fox, Stephen B., Hacker, Neville F., Hadley, Alison M., Hendley, Joy, Ho, Gwo-Yaw, Hunter, Sally M., Jobling, Tom W., Kalli, Kimberly R., Kaufmann, Scott H., Le Page, Cecile, McNally, Orla M., McAlpine, Jessica N., Mileshkin, Linda, Pyman, Jan, Samimi, Goli, Sharma, Ragwha, and Campbell, Ian G.

Published
2021
Full Text
View/download PDF

15. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms

Author

Mackenzie, Robertson, Kommoss, Stefan, Winterhoff, Boris J, Kipp, Benjamin R, Garcia, Joaquin J, Voss, Jesse, Halling, Kevin, Karnezis, Anthony, Senz, Janine, Yang, Winnie, Prigge, Elena-Sophie, Reuschenbach, Miriam, Doeberitz, Magnus Von Knebel, Gilks, Blake C, Huntsman, David G, Bakkum-Gamez, Jamie, McAlpine, Jessica N, and Anglesio, Michael S

Subjects
Cancer, Genetics, Biotechnology, Rare Diseases, Ovarian Cancer, Adenocarcinoma, Mucinous, Carcinoma, Ovarian Epithelial, Female, High-Throughput Nucleotide Sequencing, Humans, Immunohistochemistry, Mutation, Mutation Rate, Neoplasm Staging, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Signal Transduction, Tumor Suppressor Protein p53, ras Proteins, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundMucinous ovarian tumors represent a distinct histotype of epithelial ovarian cancer. The rarest (2-4 % of ovarian carcinomas) of the five major histotypes, their genomic landscape remains poorly described. We undertook hotspot sequencing of 50 genes commonly mutated in human cancer across 69 mucinous ovarian tumors. Our goals were to establish the overall frequency of cancer-hotspot mutations across a large cohort, especially those tumors previously thought to be "RAS-pathway alteration negative", using highly-sensitive next-generation sequencing as well as further explore a small number of cases with apparent heterogeneity in RAS-pathway activating alterations.MethodsUsing the Ion Torrent PGM platform, we performed next generation sequencing analysis using the v2 Cancer Hotspot Panel. Regions of disparate ERBB2-amplification status were sequenced independently for two mucinous carcinoma (MC) cases, previously established as showing ERBB2 amplification/overexpression heterogeneity, to assess the hypothesis of subclonal populations containing either KRAS mutation or ERBB2 amplification independently or simultaneously.ResultsWe detected mutations in KRAS, TP53, CDKN2A, PIK3CA, PTEN, BRAF, FGFR2, STK11, CTNNB1, SRC, SMAD4, GNA11 and ERBB2. KRAS mutations remain the most frequently observed alteration among MC (64.9 %) and mucinous borderline tumors (MBOT) (92.3 %). TP53 mutation occurred more frequently in carcinomas than borderline tumors (56.8 % and 11.5 %, respectively), and combined IHC and mutation data suggest alterations occur in approximately 68 % of MC and as many as 20 % of MBOT. Proven and potential RAS-pathway activating changes were observed in all but one MC. Concurrent ERBB2 amplification and KRAS mutation were observed in a substantial number of cases (7/63 total), as was co-occurrence of KRAS and BRAF mutations (one case). Microdissection of ERBB2-amplified regions of tumors harboring KRAS mutation suggests these alterations are occurring in the same cell populations, while consistency of KRAS allelic frequency in both ERBB2 amplified and non-amplified regions suggests this mutation occurred in advance of the amplification event.ConclusionsOverall, the prevalence of RAS-alteration and striking co-occurrence of pathway "double-hits" supports a critical role for tumor progression in this ovarian malignancy. Given the spectrum of RAS-activating mutations, it is clear that targeting this pathway may be a viable therapeutic option for patients with recurrent or advanced stage mucinous ovarian carcinoma, however caution should be exercised in selecting one or more personalized therapeutics given the frequency of non-redundant RAS-activating alterations.

Published
2015

17. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

Jamieson, Amy, primary, Vermij, Lisa, additional, Kramer, Claire J.H., additional, Jobsen, Jan J., additional, Jürgenliemk-Schulz, Ina, additional, Lutgens, Ludy, additional, Mens, Jan Willem, additional, Haverkort, Marie A.D., additional, Slot, Annerie, additional, Nout, Remi A., additional, Oosting, Jan, additional, Carlson, Joseph, additional, Howitt, Brooke E., additional, Ip, Philip P.C., additional, Lax, Sigurd F., additional, McCluggage, W. Glenn, additional, Singh, Naveena, additional, McAlpine, Jessica N., additional, Creutzberg, Carien L., additional, Horeweg, Nanda, additional, Gilks, C. Blake, additional, and Bosse, Tjalling, additional

Published
2023
Full Text
View/download PDF

18. The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas

Author

Heinze, Karolin, primary, Cairns, Evan S., additional, Thornton, Shelby, additional, Harris, Bronwyn, additional, Milne, Katy, additional, Grube, Marcel, additional, Meyer, Charlotte, additional, Karnezis, Anthony N., additional, Fereday, Sian, additional, Garsed, Dale W., additional, Leung, Samuel C.Y., additional, Chiu, Derek S., additional, Moubarak, Malak, additional, Harter, Philipp, additional, Heitz, Florian, additional, McAlpine, Jessica N., additional, DeFazio, Anna, additional, Bowtell, David D.L., additional, Goode, Ellen L., additional, Pike, Malcolm, additional, Ramus, Susan J., additional, Pearce, C. Leigh, additional, Staebler, Annette, additional, Köbel, Martin, additional, Kommoss, Stefan, additional, Talhouk, Aline, additional, Nelson, Brad H., additional, and Anglesio, Michael S., additional

Published
2023
Full Text
View/download PDF

19. Corrigendum to “Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death”: [Modern Pathology 36 (2023) 100085]

Author

Jamieson, Amy, primary, Huvila, Jutta, additional, Chiu, Derek, additional, Thompson, Emily F., additional, Scott, Stephanie, additional, Salvador, Shannon, additional, Vicus, Danielle, additional, Helpman, Limor, additional, Gotlieb, Walter, additional, Kean, Sarah, additional, Samouelian, Vanessa, additional, Köbel, Martin, additional, Kinloch, Mary, additional, Parra-Herran, Carlos, additional, Offman, Saul, additional, Grondin, Katherine, additional, Irving, Julie, additional, Lum, Amy, additional, Senz, Janine, additional, Leung, Samuel, additional, McConechy, Melissa K., additional, Plante, Marie, additional, Kommoss, Stefan, additional, Huntsman, David G., additional, Talhouk, Aline, additional, Gilks, C. Blake, additional, and McAlpine, Jessica N., additional

Published
2023
Full Text
View/download PDF

20. QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction

Author

Van den Heerik, Anne Sophie V.M., primary, Ter Haar, Natalja T., additional, Vermij, Lisa, additional, Jobsen, Jan J., additional, Brinkhuis, Mariel, additional, Roothaan, Suzan M., additional, Leon-Castillo, Alicia, additional, Ortoft, Gitte, additional, Hogdall, Estrid, additional, Hogdall, Claus, additional, Van Wezel, Tom, additional, Lutgens, Ludy C.H.W., additional, Haverkort, Marie A.D., additional, Khattra, Jas, additional, McAlpine, Jessica N., additional, Creutzberg, Carien L., additional, Smit, Vincent T.H.B.M., additional, Gilks, C. Blake, additional, Horeweg, Nanda, additional, and Bosse, Tjalling, additional

Published
2023
Full Text
View/download PDF

22. Abstract 4542: Development of a one-step molecular classifier for endometrial carcinoma using an amplicon-based gene panel and next generation sequencing technology

Author

McConechy, Melissa K., primary, Jamieson, Amy, additional, Lum, Amy, additional, Leung, Samuel, additional, Kense, Adrian, additional, Brahmbhatt, Sonal, additional, Nip, Ka Mun, additional, Baran, Ebru, additional, Perera, Dilmi, additional, Yakimovich, Kurt, additional, Miller, Ruth, additional, Gilks, C. Blake, additional, Huntsman, David, additional, and McAlpine, Jessica N., additional

Published
2023
Full Text
View/download PDF

23. Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death

Author

Jamieson, Amy, primary, Huvila, Jutta, additional, Chiu, Derek, additional, Thompson, Emily F., additional, Scott, Stephanie, additional, Salvador, Shannon, additional, Vicus, Danielle, additional, Helpman, Limor, additional, Gotlieb, Walter, additional, Kean, Sarah, additional, Samouelian, Vanessa, additional, Köbel, Martin, additional, Kinloch, Mary, additional, Parra-Harran, Carlos, additional, Offman, Saul, additional, Grondin, Katherine, additional, Irving, Julie, additional, Lum, Amy, additional, Senz, Janine, additional, Leung, Samuel, additional, McConechy, Melissa K., additional, Plante, Marie, additional, Kommoss, Stefan, additional, Huntsman, David G., additional, Talhouk, Aline, additional, Gilks, C. Blake, additional, and McAlpine, Jessica N., additional

Published
2023
Full Text
View/download PDF

24. p53-Abnormal “Fields of Dysplasia” in Human Papillomavirus–Independent Vulvar Squamous Cell Carcinoma Impacts Margins and Recurrence Risk

Author

Thompson, Emily F., primary, Wong, Richard W.C., additional, Trevisan, Giorgia, additional, Tessier-Cloutier, Basile, additional, Almadani, Noorah, additional, Chen, Julia, additional, Cheng, Angela, additional, Karnezis, Anthony, additional, McConechy, Melissa K., additional, Lum, Amy, additional, Senz, Janine, additional, McAlpine, Jessica N., additional, Huntsman, David G., additional, Gilks, Blake, additional, Jamieson, Amy, additional, and Hoang, Lynn N., additional

Published
2023
Full Text
View/download PDF

25. QPOLE:A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction

Author

Van den Heerik, Anne Sophie V.M., Ter Haar, Natalja T., Vermij, Lisa, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan M., Leon-Castillo, Alicia, Ortoft, Gitte, Hogdall, Estrid, Hogdall, Claus, Van Wezel, Tom, Lutgens, Ludy C.H.W., Haverkort, Marie A.D., Khattra, Jas, McAlpine, Jessica N., Creutzberg, Carien L., Smit, Vincent T.H.B.M., Gilks, C. Blake, Horeweg, Nanda, Bosse, Tjalling, Van den Heerik, Anne Sophie V.M., Ter Haar, Natalja T., Vermij, Lisa, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan M., Leon-Castillo, Alicia, Ortoft, Gitte, Hogdall, Estrid, Hogdall, Claus, Van Wezel, Tom, Lutgens, Ludy C.H.W., Haverkort, Marie A.D., Khattra, Jas, McAlpine, Jessica N., Creutzberg, Carien L., Smit, Vincent T.H.B.M., Gilks, C. Blake, Horeweg, Nanda, and Bosse, Tjalling

Abstract

PURPOSE: Detection of 11 pathogenic variants in the POLE gene in endometrial cancer (EC) is critically important to identify women with a good prognosis and reduce overtreatment. Currently, POLE status is determined by DNA sequencing, which can be expensive, relatively time-consuming, and unavailable in hospitals without specialized equipment and personnel. This may hamper the implementation of POLE-testing in clinical practice. To overcome this, we developed and validated a rapid, low-cost POLE hotspot test by a quantitative polymerase chain reaction (qPCR) assay, QPOLE. MATERIALS AND METHODS: Primer and fluorescence-labeled 5'-nuclease probe sequences of the 11 established pathogenic POLE mutations were designed. Three assays, QPOLE-frequent for the most common mutations and QPOLE-rare-1 and QPOLE-rare-2 for the rare variants, were developed and optimized using DNA extracted from formalin-fixed paraffin-embedded tumor tissues. The simplicity of the design enables POLE status assessment within 4-6 hours after DNA isolation. An interlaboratory external validation study was performed to determine the practical feasibility of this assay. RESULTS: Cutoffs for POLE wild-type, POLE-mutant, equivocal, and failed results were predefined on the basis of a subset of POLE mutants and POLE wild-types for the internal and external validation. For equivocal cases, additional DNA sequencing is recommended. Performance in 282 EC cases, of which 99 were POLE-mutated, demonstrated an overall accuracy of 98.6% (95% CI, 97.2 to 99.9), a sensitivity of 95.2% (95% CI, 90.7 to 99.8), and a specificity of 100%. After DNA sequencing of 8.8% equivocal cases, the final sensitivity and specificity were 96.0% (95% CI, 92.1 to 99.8) and 100%. External validation confirmed feasibility and accuracy. CONCLUSION: QPOLE is a qPCR assay that is a quick, simple, and reliable alternative for DNA sequencing. QPOLE detects all pathogenic variants in the exonuclease domain of the POLE gene. QPOLE will

Published
2023

26. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, Bosse, Tjalling, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, and Bosse, Tjalling

Abstract

PURPOSE: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review pathologic and molecular characteristics, and outcomes of stage I low-grade p53abn EEC in a large international cohort. EXPERIMENTAL DESIGN: Previously diagnosed stage I p53abn EC (POLE-wild-type, mismatch repair-proficient) low-grade EEC from Canadian retrospective cohorts and PORTEC-1&2 trials were included. Pathology review was performed by six expert gynecologic pathologists blinded to p53 status. IHC profiling, next-generation sequencing, and shallow whole-genome sequencing was performed. Kaplan-Meier method was used for survival analysis. RESULTS: We identified 55 stage I p53abn low-grade EEC among 3,387 cases (2.5%). On pathology review, 17 cases (31%) were not diagnosed as low-grade EEC by any pathologists, whereas 26 cases (47%) were diagnosed as low-grade EEC by at least three pathologists. The IHC and molecular profile of the latter cases were consistent with low-grade EEC morphology (ER/PR positivity, patchy p16 expression, PIK3CA and PTEN mutations) but they also showed features of p53abn EC (TP53 mutations, many copy-number alterations). These cases had a clinically relevant risk of disease recurrence (5-year recurrence-free survival 77%), with pelvic and/or distant recurrences observed in 12% of the patients. CONCLUSIONS:A subset of p53abn EC is morphologically low-grade EEC and exhibit genomic instability. Even for stage I disease, p53abn low-grade EEC are at substantial risk of disease recurrence. These findings highlight the clinical relevance of universal p53-testing, even in low-grade EEC, to identify women at increased risk of recurrence.

Published
2023

27. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas

Author

MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, Bosse, Tjalling, MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, and Bosse, Tjalling

Published
2023

28. The molecular origin and taxonomy of mucinous ovarian carcinoma

Author

Cheasley, Dane, Wakefield, Matthew J., Ryland, Georgina L., Allan, Prue E., Alsop, Kathryn, Amarasinghe, Kaushalya C., Ananda, Sumitra, Anglesio, Michael S., Au-Yeung, George, Böhm, Maret, Bowtell, David D. L., Brand, Alison, Chenevix-Trench, Georgia, Christie, Michael, Chiew, Yoke-Eng, Churchman, Michael, DeFazio, Anna, Demeo, Renee, Dudley, Rhiannon, Fairweather, Nicole, Fedele, Clare G., Fereday, Sian, Fox, Stephen B., Gilks, C Blake, Gourley, Charlie, Hacker, Neville F., Hadley, Alison M., Hendley, Joy, Ho, Gwo-Yaw, Hughes, Siobhan, Hunstman, David G., Hunter, Sally M., Jobling, Tom W., Kalli, Kimberly R., Kaufmann, Scott H., Kennedy, Catherine J., Köbel, Martin, Le Page, Cecile, Li, Jason, Lupat, Richard, McNally, Orla M., McAlpine, Jessica N., Mes-Masson, Anne-Marie, Mileshkin, Linda, Provencher, Diane M., Pyman, Jan, Rahimi, Kurosh, Rowley, Simone M., Salazar, Carolina, Samimi, Goli, Saunders, Hugo, Semple, Timothy, Sharma, Ragwha, Sharpe, Alice J., Stephens, Andrew N., Thio, Niko, Torres, Michelle C., Traficante, Nadia, Xing, Zhongyue, Zethoven, Magnus, Antill, Yoland C., Scott, Clare L., Campbell, Ian G., and Gorringe, Kylie L.

Published
2019
Full Text
View/download PDF

33. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

Author

Le Page, Cécile, Rahimi, Kurosh, Köbel, Martin, Tonin, Patricia N., Meunier, Liliane, Portelance, Lise, Bernard, Monique, Nelson, Brad H., Bernardini, Marcus Q., Bartlett, John M. S., Bachvarov, Dimcho, Gotlieb, Walter H., Gilks, Blake, McAlpine, Jessica N., Nachtigal, Mark W., Piché, Alain, Watson, Peter H., Vanderhyden, Barbara, Huntsman, David G., Provencher, Diane M., and Mes-Masson, Anne-Marie

Published
2018
Full Text
View/download PDF

36. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma

Author

Sengal, Asmerom, Smith, Deborah, Snell, Cameron, Leung, Samuel C. Y., Talhouk, Aline, Williams, Elizabeth, McAlpine, Jessica N., Pollock, Pamela, Sengal, Asmerom, Smith, Deborah, Snell, Cameron, Leung, Samuel C. Y., Talhouk, Aline, Williams, Elizabeth, McAlpine, Jessica N., and Pollock, Pamela

Abstract

Endometrial carcinoma (EC) is the most common gynecological malignancy and fibroblast growth factor receptor 2 (FGFR2) is a frequently dysregulated receptor tyrosine kinase. FGFR2b and FGFR2c are the two main splice isoforms of FGFR2 and are normally localized in epithelial and mesenchymal cells, respectively. Previously, we demonstrated that FGFR2c mRNA expression was associated with aggressive tumor characteristics, shorter progression-free survival (PFS), and disease-specific survival (DSS) in endometrioid ECs (EECs). The objectives of this study were to investigate the spatial expression of FGFR2b in normal and hyperplasia with and without atypia of human endometrium and to assess the prognostic significance of FGFR2b expression in EC. FGFR2b and FGFR2c mRNA expression was evaluated in normal (proliferative [n = 10], secretory [n = 15], and atrophic [n = 10] endometrium), hyperplasia with and without atypia (n = 19) as well as two patient cohorts of EC samples (discovery [n = 78] and Vancouver [n = 460]) using isoform-specific BaseScope RNA in situ hybridization assays. Tumors were categorized based on FGFR2 isoform expression (one, both, or neither) and categories were correlated with clinicopathologic markers, molecular subtypes, and clinical outcomes. The FGFR2b splice isoform was exclusively expressed in the epithelial compartment of normal endometrium and hyperplasia without atypia. We observed FGFR2c expression at the basalis layer of glands in 33% (3/9) of hyperplasia with atypia. In patients with EEC, FGFR2b+/FGFR2c− expression was found in 48% of the discovery cohort and 35% of the validation Vancouver cohort. In univariate analyses, tumors with FGFR2b+/FGFR2c− expression had longer PFS (hazard ratio [HR] 0.265; 95% CI 0.145–0.423; log-rank p < 0.019) and DSS (HR 0.31; 95% CI 0.149–0.622; log-rank p < 0.001) compared to tumors with FGFR2b−/FGFR2c+ expression in the large EEC Vancouver cohort. In multivariable Cox regression analyses, tumors with FGFR

Published
2022

37. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma

Author

Lee, Cheng-Han, Ou, Wen-Bin, Mariño-Enriquez, Adrian, Zhu, Meijun, Mayeda, Mark, Wang, Yuexiang, Guo, Xiangqian, Brunner, Alayne L., Amant, Frédéric, French, Christopher A., West, Robert B., McAlpine, Jessica N., Gilks, C. Blake, Yaffe, Michael B., Prentice, Leah M., McPherson, Andrew, Jones, Steven J. M., Marra, Marco A., Shah, Sohrab P., van de Rijn, Matt, Huntsman, David G., Cin, Paola Dal, Debiec-Rychter, Maria, Nucci, Marisa R., and Fletcher, Jonathan A.

Published
2012

41. Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma.

Author

Sengal, Asmerom T, Smith, Deborah, Snell, Cameron E, Leung, Samuel, Talhouk, Aline, Williams, Elizabeth D, McAlpine, Jessica N, and Pollock, Pamela M

Subjects
ENDOMETRIAL cancer, FIBROBLAST growth factor 2, FIBROBLAST growth factor receptors, ENDOMETRIUM, NUCLEIC acid hybridization, BIOMARKERS
Abstract

Endometrial carcinoma (EC) is the most common gynecological malignancy and fibroblast growth factor receptor 2 (FGFR2) is a frequently dysregulated receptor tyrosine kinase. FGFR2b and FGFR2c are the two main splice isoforms of FGFR2 and are normally localized in epithelial and mesenchymal cells, respectively. Previously, we demonstrated that FGFR2c mRNA expression was associated with aggressive tumor characteristics, shorter progression‐free survival (PFS), and disease‐specific survival (DSS) in endometrioid ECs (EECs). The objectives of this study were to investigate the spatial expression of FGFR2b in normal and hyperplasia with and without atypia of human endometrium and to assess the prognostic significance of FGFR2b expression in EC. FGFR2b and FGFR2c mRNA expression was evaluated in normal (proliferative [n = 10], secretory [n = 15], and atrophic [n = 10] endometrium), hyperplasia with and without atypia (n = 19) as well as two patient cohorts of EC samples (discovery [n = 78] and Vancouver [n = 460]) using isoform‐specific BaseScope RNA in situ hybridization assays. Tumors were categorized based on FGFR2 isoform expression (one, both, or neither) and categories were correlated with clinicopathologic markers, molecular subtypes, and clinical outcomes. The FGFR2b splice isoform was exclusively expressed in the epithelial compartment of normal endometrium and hyperplasia without atypia. We observed FGFR2c expression at the basalis layer of glands in 33% (3/9) of hyperplasia with atypia. In patients with EEC, FGFR2b+/FGFR2c− expression was found in 48% of the discovery cohort and 35% of the validation Vancouver cohort. In univariate analyses, tumors with FGFR2b+/FGFR2c− expression had longer PFS (hazard ratio [HR] 0.265; 95% CI 0.145–0.423; log‐rank p < 0.019) and DSS (HR 0.31; 95% CI 0.149–0.622; log‐rank p < 0.001) compared to tumors with FGFR2b−/FGFR2c+ expression in the large EEC Vancouver cohort. In multivariable Cox regression analyses, tumors with FGFR2b+/FGFR2c− expression were significantly associated with longer DSS (HR 0.37; 95% CI 0.153–0.872; log‐rank p < 0.023) compared to FGFR2b−/FGFR2c+ tumors. In conclusion, FGFR2b+/FGFR2c− expression is associated with favorable clinicopathologic markers and clinical outcomes suggesting that FGFR2b could play a role in tailoring the management of EEC patients in the clinic if these findings are confirmed in an independent cohort. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes

Author

Sengal, Asmerom T., Patch, Ann-Marie, Snell, Cameron E., Smith, Deborah S., Leung, Samuel C.Y., Talhouk, Aline, Williams, Elizabeth D., McAlpine, Jessica N., Pollock, Pamela M., Sengal, Asmerom T., Patch, Ann-Marie, Snell, Cameron E., Smith, Deborah S., Leung, Samuel C.Y., Talhouk, Aline, Williams, Elizabeth D., McAlpine, Jessica N., and Pollock, Pamela M.

Abstract

Purpose: The two most common molecular subtypes of endometrial cancers, mismatch repair deficient (MMRd) and p53 wild-type (p53wt) comprise the majority of endometrial cancers and have intermediate prognoses where additional risk stratification biomarkers are needed. Isoform switching of FGFR2 from FGFR2b to FGFR2c (normally expressed in mesenchymal cells), has been reported in other solid carcinomas. The objective of this study was to investigate the role of FGFR2c in risk stratification of endometrial cancer. Experimental Design: We have developed and optimized a BaseScope RNA ISH assay to detect FGFR2c. FGFR2c expression was determined in a preliminary screening cohort of 78 endometrial cancers and a clinically and molecularly annotated Vancouver cohort (n ¼ 465). Cox regression model analyses were performed to assess the prognostic value of FGFR2c. Results: Univariate and multivariate analyses revealed FGFR2c expression was significantly associated with shorter disease-specific survival (DSS) and progression-free survival (PFS) in endometrioid endometrial cancer (EEC, n ¼ 302). Notably, FGFR2c expression was significantly associated with shorter PFS and DSS in patients with grade 3 EECs (P < 0.003 and P < 0.002) and the European Society Medical Oncology (ESMO) high-risk group (P < 0.0001 and P < 0.002), respectively. Moreover, within the MMRd subtype, FGFR2c expression was significantly associated with shorter PFS (P < 0.048) and DSS (P < 0.001). Conclusions: FGFR2c expression appears an independent prognostic biomarker in patients with EEC and further discerns the outcomes within grade 3 tumors, ESMO high-risk groups, as well as within the MMRd and p53wt subtypes. FGFR2c inclusion into future molecular subtyping can further refine risk stratification of EEC.

Published
2020

45. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma

Author

Krämer, Pauline, primary, Talhouk, Aline, additional, Brett, Mary Anne, additional, Chiu, Derek S., additional, Cairns, Evan S., additional, Scheunhage, Daniëlla A., additional, Hammond, Rory F.L., additional, Farnell, David, additional, Nazeran, Tayyebeh M., additional, Grube, Marcel, additional, Xia, Zhouchunyang, additional, Senz, Janine, additional, Leung, Samuel, additional, Feil, Lukas, additional, Pasternak, Jana, additional, Dixon, Katherine, additional, Hartkopf, Andreas, additional, Krämer, Bernhard, additional, Brucker, Sara, additional, Heitz, Florian, additional, du Bois, Andreas, additional, Harter, Philipp, additional, Kommoss, Felix K.F., additional, Sinn, Hans-Peter, additional, Heublein, Sabine, additional, Kommoss, Friedrich, additional, Vollert, Hans-Walter, additional, Manchanda, Ranjit, additional, de Kroon, Cornelis D., additional, Nijman, Hans W., additional, de Bruyn, Marco, additional, Thompson, Emily F., additional, Bashashati, Ali, additional, McAlpine, Jessica N., additional, Singh, Naveena, additional, Tinker, Anna V., additional, Staebler, Annette, additional, Bosse, Tjalling, additional, Kommoss, Stefan, additional, Köbel, Martin, additional, and Anglesio, Michael S., additional

Published
2020
Full Text
View/download PDF

46. Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line

Author

Wang, Yemin, primary, Tao, Valerie Lan, additional, Shin, Chae Young, additional, Salamanca, Clara, additional, Chen, Shary Yuting, additional, Chow, Christine, additional, Köbel, Martin, additional, Ben-Neriah, Susana, additional, Farnell, David, additional, Steidl, Christian, additional, Mcalpine, Jessica N., additional, Gilks, C. Blake, additional, and Huntsman, David G., additional

Published
2020
Full Text
View/download PDF

48. Fertility-sparing treatment in early endometrial cancer: current state and future strategies

Author

Obermair, Andreas, primary, Baxter, Eva, additional, Brennan, Donal J., additional, McAlpine, Jessica N., additional, Muellerer, Jennifer J., additional, Amant, Frédéric, additional, van Gent, Mignon D. J. M., additional, Coleman, Robert L., additional, Westin, Shannon N., additional, Yates, Melinda S., additional, Krakstad, Camilla, additional, and Janda, Monika, additional

Published
2020
Full Text
View/download PDF

49. Abstract B09: Single-cell RNA sequencing of normal endometrial organoids uncovers novel cell-type markers for prognostication of primary tumor samples

Author

Cochrane, Dawn R., primary, Campbell, Kieran R., additional, Greening, Kendall, additional, Ho, Germain C., additional, Hopkins, James, additional, Bui, Minh, additional, Sharlandjieva, Vassilena, additional, Lai, Daniel, additional, DeGrood, Maya, additional, Gibbard, Evan W., additional, Leung, Samuel, additional, Cheng, Angela S., additional, Lim, Jamie L.P., additional, Neilson, Samantha, additional, Farnell, David, additional, Kommoss, Friedrich, additional, McAlpine, Jessica N., additional, Shah, Sohrab P., additional, and Huntsman, David G., additional

Published
2020
Full Text
View/download PDF

50. BRCA1Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis

Author

Kalachand, Roshni D, primary, Stordal, Britta, additional, Madden, Stephen, additional, Chandler, Benjamin, additional, Cunningham, Julie, additional, Goode, Ellen L, additional, Ruscito, Ilary, additional, Braicu, Elena I, additional, Sehouli, Jalid, additional, Ignatov, Atanas, additional, Yu, Herbert, additional, Katsaros, Dionyssios, additional, Mills, Gordon B, additional, Lu, Karen H, additional, Carey, Mark S, additional, Timms, Kirsten M, additional, Kupryjanczyk, Jolanta, additional, Rzepecka, Iwona K, additional, Podgorska, Agnieszka, additional, McAlpine, Jessica N, additional, Swisher, Elizabeth M, additional, Bernards, Sarah S, additional, O’Riain, Ciaran, additional, O’Toole, Sharon, additional, O’Leary, John J, additional, Bowtell, David D, additional, Thomas, David M, additional, Prieske, Katharina, additional, Joosse, Simon A, additional, Woelber, Linn, additional, Chaudhry, Parvesh, additional, Häfner, Norman, additional, Runnebaum, Ingo B, additional, and Hennessy, Bryan T, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results